Gastric and Esophageal Cancer Drug Development Pipeline Review, 2017

This report provides an overview of the Gastric and Esophageal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for each of these cancer types, and features dormant and discontinued projects.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. There are a total of 322 products in development for this indication, by 208 companies and 22 academic institutions. Key companies operating in this pipeline space include Eli Lilly, Roche, Bristol-Myers Squibb, Incyte, Pfizer and AstraZeneca.

Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. There are a total of 107 products in development for this indication, by 79 companies and 11 academic institutions.

Key targets in development across both indications include human epidermal growth factors 1 and 2, and programmed cell death protein 1. In addition, the hepatocyte and vascular endothelial growth factors are being developed across many pipeline programs in gastric cancer.

Scope

– Which companies are the most active within each pipeline?

– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

– What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 9

2 Introduction 10

2.1 Gastric and Esophageal Cancer Report Coverage 10

2.2 Esophageal Cancer – Overview 10

2.3 Gastric Cancer – Overview 10

3 Therapeutics Development 11

3.1 Esophageal Cancer 11

3.2 Gastric Cancer 21

4 Therapeutics Assessment 45

4.1 Esophageal Cancer 45

4.2 Gastric Cancer 56

5 Companies Involved in Therapeutics Development 78

5.1 Esophageal Cancer 78

5.2 Gastric Cancer 109

6 Dormant Projects 187

6.1 Esophageal Cancer 187

6.2 Gastric Cancer 190

7 Discontinued Products 198

7.1 Esophageal Cancer 198

7.2 Gastric Cancer 199

8 Product Development Milestones 202

8.1 Esophageal Cancer 202

8.2 Gastric Cancer 218

9 Appendix 243

9.1 Methodology 243

9.2 Coverage 243

9.3 Secondary Research 243

9.4 Primary Research 243

9.5 Expert Panel Validation 243

9.6 Contact Us 244

9.7 Disclaimer 244

List of Tables

1.1 List of Tables

Table 1: Number of Products under Development for Esophageal Cancer 11

Table 2: Number of Products under Development by Companies, Esophageal Cancer 13

Table 3: Number of Products under Development by Universities/Institutes, Esophageal Cancer 15

Table 4: Products under Development by Companies, Esophageal Cancer 16

Table 5: Products under Development by Universities/Institutes, Esophageal Cancer 20

Table 6: Number of Products under Development for Gastric Cancer 21

Table 7: Number of Products under Development by Companies, Gastric Cancer 23

Table 8: Number of Products under Development by Universities/Institutes, Gastric Cancer 30

Table 9: Products under Development by Companies, Gastric Cancer 31

Table 10: Products under Development by Universities/Institutes, Gastric Cancer 43

Table 11: Number of Products by Stage and Target, Esophageal Cancer 46

Table 12: Number of Products by Stage and Mechanism of Action, Esophageal Cancer 50

Table 13: Number of Products by Stage and Route of Administration, Esophageal Cancer 54

Table 14: Number of Products by Stage and Molecule Type, Esophageal Cancer 56

Table 15: Number of Products by Stage and Target, Gastric Cancer 58

Table 16: Number of Products by Stage and Mechanism of Action, Gastric Cancer 66

Table 17: Number of Products by Stage and Route of Administration, Gastric Cancer 75

Table 18: Number of Products by Stage and Molecule Type, Gastric Cancer 77

Table 19: Esophageal Cancer – Pipeline by Adaptimmune Therapeutics Plc 78

Table 20: Esophageal Cancer – Pipeline by ADC Therapeutics Sarl 78

Table 21: Esophageal Cancer – Pipeline by Aduro BioTech Inc 79

Table 22: Esophageal Cancer – Pipeline by Advenchen Laboratories LLC 79

Table 23: Esophageal Cancer – Pipeline by Almac Discovery Ltd 80

Table 24: Esophageal Cancer – Pipeline by Ambrx Inc 80

Table 25: Esophageal Cancer – Pipeline by Amgen Inc 81

Table 26: Esophageal Cancer – Pipeline by Aprea AB 81

Table 27: Esophageal Cancer – Pipeline by ArQule Inc 82

Table 28: Esophageal Cancer – Pipeline by Array BioPharma Inc 82

Table 29: Esophageal Cancer – Pipeline by Aslan Pharmaceuticals Pte Ltd 83

Table 30: Esophageal Cancer – Pipeline by Bayer AG 83

Table 31: Esophageal Cancer – Pipeline by BeiGene Ltd 84

Table 32: Esophageal Cancer – Pipeline by BioStar Pharmaceuticals Inc 84

Table 33: Esophageal Cancer – Pipeline by Boehringer Ingelheim GmbH 85

Table 34: Esophageal Cancer – Pipeline by Bristol-Myers Squibb Co 85

Table 35: Esophageal Cancer – Pipeline by Cascadian Therapeutics Inc 86

Table 36: Esophageal Cancer – Pipeline by CBT Pharmaceuticals Inc 86

Table 37: Esophageal Cancer – Pipeline by Celgene Corp 87

Table 38: Esophageal Cancer – Pipeline by Celldex Therapeutics Inc 87

Table 39: Esophageal Cancer – Pipeline by Cellectar Biosciences Inc 88

Table 40: Esophageal Cancer – Pipeline by Clovis Oncology Inc 88

Table 41: Esophageal Cancer – Pipeline by Cyclacel Pharmaceuticals Inc 89

Table 42: Esophageal Cancer – Pipeline by DAE HWA Pharmaceutical Co Ltd 89

Table 43: Esophageal Cancer – Pipeline by Eli Lilly and Co 90

Table 44: Esophageal Cancer – Pipeline by F. Hoffmann-La Roche Ltd 90

Table 45: Esophageal Cancer – Pipeline by Genmab A/S 91

Table 46: Esophageal Cancer – Pipeline by GlaxoSmithKline Plc 92

Table 47: Esophageal Cancer – Pipeline by Glycotope GmbH 92

Table 48: Esophageal Cancer – Pipeline by Hanmi Pharmaceuticals Co Ltd 92

Table 49: Esophageal Cancer – Pipeline by Hutchison MediPharma Ltd 93

Table 50: Esophageal Cancer – Pipeline by Ignyta Inc 93

Table 51: Esophageal Cancer – Pipeline by Immunocore Ltd 94

Table 52: Esophageal Cancer – Pipeline by ImmunoFrontier Inc 94

Table 53: Esophageal Cancer – Pipeline by Immunomedics Inc 95

Table 54: Esophageal Cancer – Pipeline by Incyte Corp 95

Table 55: Esophageal Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd 96

Table 56: Esophageal Cancer – Pipeline by Johnson & Johnson 96

Table 57: Esophageal Cancer – Pipeline by Leap Therapeutics Inc 97

Table 58: Esophageal Cancer – Pipeline by Madrigal Pharmaceuticals Inc. 97

Table 59: Esophageal Cancer – Pipeline by MaxiVAX SA 98

Table 60: Esophageal Cancer – Pipeline by Mebiopharm Co Ltd 98

Table 61: Esophageal Cancer – Pipeline by MedImmune LLC 99

Table 62: Esophageal Cancer – Pipeline by Merck & Co Inc 99

Table 63: Esophageal Cancer – Pipeline by Merrimack Pharmaceuticals Inc 100

Table 64: Esophageal Cancer – Pipeline by Novartis AG 100

Table 65: Esophageal Cancer – Pipeline by Omeros Corp 101

Table 66: Esophageal Cancer – Pipeline by Omnitura Therapeutics Inc 101

Table 67: Esophageal Cancer – Pipeline by Oncolys BioPharma Inc 102

Table 68: Esophageal Cancer – Pipeline by Ono Pharmaceutical Co Ltd 103

Table 69: Esophageal Cancer – Pipeline by Puma Biotechnology Inc 103

Table 70: Esophageal Cancer – Pipeline by Rhizen Pharmaceuticals SA 103

Table 71: Esophageal Cancer – Pipeline by Shionogi & Co Ltd 104

Table 72: Esophageal Cancer – Pipeline by Spectrum Pharmaceuticals Inc 104

Table 73: Esophageal Cancer – Pipeline by Steba Biotech SA 105

Table 74: Esophageal Cancer – Pipeline by Stelic Institute & Co Inc 105

Table 75: Esophageal Cancer – Pipeline by Supratek Pharma Inc 106

Table 76: Esophageal Cancer – Pipeline by Symphogen A/S 106

Table 77: Esophageal Cancer – Pipeline by Taiho Pharmaceutical Co Ltd 106

Table 78: Esophageal Cancer – Pipeline by Taiwan Liposome Company Ltd 107

Table 79: Esophageal Cancer – Pipeline by Takara Bio Inc 107

Table 80: Esophageal Cancer – Pipeline by Transgene Biotek Ltd 108

Table 81: Esophageal Cancer – Pipeline by XuanZhu Pharma Co Ltd 108

Table 82: Gastric Cancer – Pipeline by 3SBio Inc 109

Table 83: Gastric Cancer – Pipeline by AbbVie Inc 110

Table 84: Gastric Cancer – Pipeline by AbGenomics International Inc 110

Table 85: Gastric Cancer – Pipeline by Abion Inc 111

Table 86: Gastric Cancer – Pipeline by Adaptimmune Therapeutics Plc 111

Table 87: Gastric Cancer – Pipeline by ADC Therapeutics Sarl 111

Table 88: Gastric Cancer – Pipeline by Aduro BioTech Inc 112

Table 89: Gastric Cancer – Pipeline by Advenchen Laboratories LLC 112

Table 90: Gastric Cancer – Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd 113

Table 91: Gastric Cancer – Pipeline by Almac Discovery Ltd 113

Table 92: Gastric Cancer – Pipeline by Alteogen Inc 114

Table 93: Gastric Cancer – Pipeline by Ambrx Inc 114

Table 94: Gastric Cancer – Pipeline by amcure GmbH 115

Table 95: Gastric Cancer – Pipeline by Amgen Inc 115

Table 96: Gastric Cancer – Pipeline by ANP Technologies Inc 116

Table 97: Gastric Cancer – Pipeline by Antikor Biopharma Ltd 116

Table 98: Gastric Cancer – Pipeline by arGEN-X BV 117

Table 99: Gastric Cancer – Pipeline by Array BioPharma Inc 117

Table 100: Gastric Cancer – Pipeline by Asana BioSciences LLC 118

Table 101: Gastric Cancer – Pipeline by Aslan Pharmaceuticals Pte Ltd 118

Table 102: Gastric Cancer – Pipeline by Astellas Pharma Inc 119

Table 103: Gastric Cancer – Pipeline by AstraZeneca Plc 120

Table 104: Gastric Cancer – Pipeline by Athenex Inc 120

Table 105: Gastric Cancer – Pipeline by Basilea Pharmaceutica Ltd 120

Table 106: Gastric Cancer – Pipeline by Bayer AG 121

Table 107: Gastric Cancer – Pipeline by BeiGene Ltd 122

Table 108: Gastric Cancer – Pipeline by Beijing Hanmi Pharmaceutical Co Ltd 122

Table 109: Gastric Cancer – Pipeline by Betta Pharmaceuticals Co Ltd 123

Table 110: Gastric Cancer – Pipeline by Biocon Ltd 123

Table 111: Gastric Cancer – Pipeline by Bioleaders Corp 123

Table 112: Gastric Cancer – Pipeline by Bionovis SA 124

Table 113: Gastric Cancer – Pipeline by Boehringer Ingelheim GmbH 124

Table 114: Gastric Cancer – Pipeline by Bristol-Myers Squibb Co 125

Table 115: Gastric Cancer – Pipeline by Camel-IDS NV 126

Table 116: Gastric Cancer – Pipeline by Cancer Prevention Pharmaceuticals Inc 126

Table 117: Gastric Cancer – Pipeline by Cascadian Therapeutics Inc 126

Table 118: Gastric Cancer – Pipeline by CBT Pharmaceuticals Inc 127

Table 119: Gastric Cancer – Pipeline by Celgene Corp 127

Table 120: Gastric Cancer – Pipeline by Celldex Therapeutics Inc 128

Table 121: Gastric Cancer – Pipeline by Cellectar Biosciences Inc 129

Table 122: Gastric Cancer – Pipeline by Celltrion Inc 129

Table 123: Gastric Cancer – Pipeline by Celon Pharma SA 130

Table 124: Gastric Cancer – Pipeline by Chipscreen Biosciences Ltd 130

Table 125: Gastric Cancer – Pipeline by Chugai Pharmaceutical Co Ltd 131

Table 126: Gastric Cancer – Pipeline by Curaxys SL 131

Table 127: Gastric Cancer – Pipeline by Cytori Therapeutics Inc 132

Table 128: Gastric Cancer – Pipeline by Daiichi Sankyo Co Ltd 132

Table 129: Gastric Cancer – Pipeline by Debiopharm International SA 133

Table 130: Gastric Cancer – Pipeline by Deciphera Pharmaceuticals LLC 133

Table 131: Gastric Cancer – Pipeline by Dr. Reddy’s Laboratories Ltd 134

Table 132: Gastric Cancer – Pipeline by Eddingpharm Inc 134

Table 133: Gastric Cancer – Pipeline by Eli Lilly and Co 135

Table 134: Gastric Cancer – Pipeline by EOS Biosciences Inc 136

Table 135: Gastric Cancer – Pipeline by Erytech Pharma SA 136

Table 136: Gastric Cancer – Pipeline by Esperance Pharmaceuticals Inc 136

Table 137: Gastric Cancer – Pipeline by Exelixis Inc 137

Table 138: Gastric Cancer – Pipeline by F-star Biotechnology Ltd 137

Table 139: Gastric Cancer – Pipeline by F. Hoffmann-La Roche Ltd 138

Table 140: Gastric Cancer – Pipeline by Five Prime Therapeutics Inc 139

Table 141: Gastric Cancer – Pipeline by Frost Biologic Inc 139

Table 142: Gastric Cancer – Pipeline by Galena Biopharma Inc 140

Table 143: Gastric Cancer – Pipeline by Genelux Corp 140

Table 144: Gastric Cancer – Pipeline by Genentech Inc 140

Table 145: Gastric Cancer – Pipeline by Gilead Sciences Inc 141

Table 146: Gastric Cancer – Pipeline by GlaxoSmithKline Plc 142

Table 147: Gastric Cancer – Pipeline by Glenmark Pharmaceuticals Ltd 142

Table 148: Gastric Cancer – Pipeline by GlycoNex Inc 143

Table 149: Gastric Cancer – Pipeline by Glycotope GmbH 143

Table 150: Gastric Cancer – Pipeline by Green Cross Corp 144

Table 151: Gastric Cancer – Pipeline by Halozyme Therapeutics Inc 144

Table 152: Gastric Cancer – Pipeline by Hanmi Pharmaceuticals Co Ltd 145

Table 153: Gastric Cancer – Pipeline by Horizon Pharma Plc 145

Table 154: Gastric Cancer – Pipeline by Humanigen Inc 146

Table 155: Gastric Cancer – Pipeline by Hummingbird Bioscience Pte Ltd 146

Table 156: Gastric Cancer – Pipeline by Hutchison MediPharma Ltd 147

Table 157: Gastric Cancer – Pipeline by Ignyta Inc 147

Table 158: Gastric Cancer – Pipeline by Ildong Pharmaceutical Co Ltd 148

Table 159: Gastric Cancer – Pipeline by Immunomedics Inc 149

Table 160: Gastric Cancer – Pipeline by Incyte Corp 149

Table 161: Gastric Cancer – Pipeline by Inovio Pharmaceuticals Inc 150

Table 162: Gastric Cancer – Pipeline by Inspyr Therapeutics Inc 150

Table 163: Gastric Cancer – Pipeline by Insys Therapeutics Inc 151

Table 164: Gastric Cancer – Pipeline by Ipsen SA 151

Table 165: Gastric Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd 152

Table 166: Gastric Cancer – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd 153

Table 167: Gastric Cancer – Pipeline by Johnson & Johnson 153

Table 168: Gastric Cancer – Pipeline by Jounce Therapeutics Inc 154

Table 169: Gastric Cancer – Pipeline by Konruns Pharmaceutical Co Ltd 154

Table 170: Gastric Cancer – Pipeline by Kringle Pharma Inc 155

Table 171: Gastric Cancer – Pipeline by Kuhnil Pharmaceutical Co Ltd 155

Table 172: Gastric Cancer – Pipeline by Kyowa Hakko Kirin Co Ltd 156

Table 173: Gastric Cancer – Pipeline by LATITUDE Pharmaceuticals Inc 156

Table 174: Gastric Cancer – Pipeline by LegoChem Biosciences Inc 157

Table 175: Gastric Cancer – Pipeline by LinXis BV 157

Table 176: Gastric Cancer – Pipeline by MacroGenics Inc 158

Table 177: Gastric Cancer – Pipeline by Madrigal Pharmaceuticals Inc. 158

Table 178: Gastric Cancer – Pipeline by MaxiVAX SA 158

Table 179: Gastric Cancer – Pipeline by Mebiopharm Co Ltd 159

Table 180: Gastric Cancer – Pipeline by MedImmune LLC 159

Table 181: Gastric Cancer – Pipeline by Merck & Co Inc 160

Table 182: Gastric Cancer – Pipeline by Merck KGaA 160

Table 183: Gastric Cancer – Pipeline by Merrimack Pharmaceuticals Inc 161

Table 184: Gastric Cancer – Pipeline by Mersana Therapeutics Inc 161

Table 185: Gastric Cancer – Pipeline by Merus NV 162

Table 186: Gastric Cancer – Pipeline by Mirati Therapeutics Inc 162

Table 187: Gastric Cancer – Pipeline by Molecular Partners AG 163

Table 188: Gastric Cancer – Pipeline by Molecular Targeting Technologies Inc 163

Table 189: Gastric Cancer – Pipeline by Moleculin Biotech Inc 164

Table 190: Gastric Cancer – Pipeline by MolMed SpA 164

Table 191: Gastric Cancer – Pipeline by NanoCarrier Co Ltd 165

Table 192: Gastric Cancer – Pipeline by Novartis AG 166

Table 193: Gastric Cancer – Pipeline by Novogen Ltd 166

Table 194: Gastric Cancer – Pipeline by OBI Pharma Inc 167

Table 195: Gastric Cancer – Pipeline by Oncobiologics Inc 167

Table 196: Gastric Cancer – Pipeline by Oncolys BioPharma Inc 168

Table 197: Gastric Cancer – Pipeline by OncoMed Pharmaceuticals Inc 168

Table 198: Gastric Cancer – Pipeline by OncoResponse Inc 169

Table 199: Gastric Cancer – Pipeline by Ono Pharmaceutical Co Ltd 169

Table 200: Gastric Cancer – Pipeline by Opsona Therapeutics Ltd 170

Table 201: Gastric Cancer – Pipeline by Patrys Ltd 170

Table 202: Gastric Cancer – Pipeline by Pfizer Inc 171

Table 203: Gastric Cancer – Pipeline by Pharma Mar SA 171

Table 204: Gastric Cancer – Pipeline by Pieris Pharmaceuticals Inc 172

Table 205: Gastric Cancer – Pipeline by Plexxikon Inc 172

Table 206: Gastric Cancer – Pipeline by Prescient Therapeutics Ltd 173

Table 207: Gastric Cancer – Pipeline by Puma Biotechnology Inc 173

Table 208: Gastric Cancer – Pipeline by Redx Pharma Plc 173

Table 209: Gastric Cancer – Pipeline by Rhizen Pharmaceuticals SA 174

Table 210: Gastric Cancer – Pipeline by Richter Gedeon Nyrt 174

Table 211: Gastric Cancer – Pipeline by Samumed LLC 175

Table 212: Gastric Cancer – Pipeline by Sanofi 175

Table 213: Gastric Cancer – Pipeline by Selecta Biosciences Inc 176

Table 214: Gastric Cancer – Pipeline by Sequella Inc 176

Table 215: Gastric Cancer – Pipeline by Shionogi & Co Ltd 177

Table 216: Gastric Cancer – Pipeline by Simcere Pharmaceutical Group 177

Table 217: Gastric Cancer – Pipeline by Sorrento Therapeutics Inc 178

Table 218: Gastric Cancer – Pipeline by Spectrum Pharmaceuticals Inc 178

Table 219: Gastric Cancer – Pipeline by Stelic Institute & Co Inc 179

Table 220: Gastric Cancer – Pipeline by Supratek Pharma Inc 179

Table 221: Gastric Cancer – Pipeline by SynCore Biotechnology Co Ltd 180

Table 222: Gastric Cancer – Pipeline by Synovo GmbH 180

Table 223: Gastric Cancer – Pipeline by Synthon Holdings BV 180

Table 224: Gastric Cancer – Pipeline by Taiho Pharmaceutical Co Ltd 181

Table 225: Gastric Cancer – Pipeline by Taiwan Liposome Company Ltd 182

Table 226: Gastric Cancer – Pipeline by Takis Srl 182

Table 227: Gastric Cancer – Pipeline by Tessa Therapeutics Pte Ltd 182

Table 228: Gastric Cancer – Pipeline by Transgene SA 183

Table 229: Gastric Cancer – Pipeline by Tyrogenex Inc 183

Table 230: Gastric Cancer – Pipeline by United BioPharma Inc 184

Table 231: Gastric Cancer – Pipeline by Vaxon Biotech 184

Table 232: Gastric Cancer – Pipeline by ViiV Healthcare Ltd 184

Table 233: Gastric Cancer – Pipeline by Viracta Therapeutics Inc 185

Table 234: Gastric Cancer – Pipeline by XuanZhu Pharma Co Ltd 185

Table 235: Gastric Cancer – Pipeline by Zymeworks Inc 186

Table 236: Esophageal Cancer – Dormant Projects 187

Table 237: Gastric Cancer – Dormant Projects 190

Table 238: Esophageal Cancer – Discontinued Products 198

Table 239: Gastric Cancer – Discontinued Products 199

List of Figures

1.2 List of Figures

Figure 1: Number of Products under Development for Esophageal Cancer 11

Figure 2: Number of Products under Development by Companies, Esophageal Cancer 12

Figure 3: Number of Products under Development by Universities/Institutes, Esophageal Cancer 15

Figure 4: Number of Products under Development for Gastric Cancer 21

Figure 5: Number of Products under Development by Companies, Gastric Cancer 22

Figure 6: Number of Products under Development by Universities/Institutes, Gastric Cancer 29

Figure 7: Number of Products by Top 10 Targets, Esophageal Cancer 45

Figure 8: Number of Products by Stage and Top 10 Targets, Esophageal Cancer 45

Figure 9: Number of Products by Top 10 Mechanism of Actions, Esophageal Cancer 49

Figure 10: Number of Products by Stage and Top 10 Mechanism of Actions, Esophageal Cancer 49

Figure 11: Number of Products by Top 10 Routes of Administration, Esophageal Cancer 53

Figure 12: Number of Products by Stage and Top 10 Routes of Administration, Esophageal Cancer 53

Figure 13: Number of Products by Top 10 Molecule Types, Esophageal Cancer 55

Figure 14: Number of Products by Stage and Top 10 Molecule Types, Esophageal Cancer 55

Figure 15: Number of Products by Top 10 Targets, Gastric Cancer 56

Figure 16: Number of Products by Stage and Top 10 Targets, Gastric Cancer 57

Figure 17: Number of Products by Top 10 Mechanism of Actions, Gastric Cancer 64

Figure 18: Number of Products by Stage and Top 10 Mechanism of Actions, Gastric Cancer 65

Figure 19: Number of Products by Routes of Administration, Gastric Cancer 74

Figure 20: Number of Products by Stage and Routes of Administration, Gastric Cancer 75

Figure 21: Number of Products by Top 10 Molecule Types, Gastric Cancer 76

Figure 22: Number of Products by Stage and Top 10 Molecule Types, Gastric Cancer 76

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports